Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances

Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapy for individuals with generalized myasthenia gravis and its impact on outcomes and steroid reduction in real-world practice. Additional details about MINT may be found in the following publication: The New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056...) . For more information on the medication discussed in this episode, please refer to the Full Prescribing Information (https://www.pi.amgen.com/-/media/Proj...)  provided by Amgen, last updated 12/2025.